Search Results - "GIULIODORI, L"

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) by CASCINU, S, SILVA, R. R, FUSCO, V, LUPORINI, G, CELLERINO, R, CATALANO, G, BARNI, S, LABIANCA, R, FRONTINI, L, PIAZZA, E, PANCERA, G, GIORDANI, P, GIULIODORI, L, PESSI, M. A

“…In a randomized clinical trial, gemcitabine (GEM) was more effective than 5-fluorouracil (5-FU) in advanced pancreatic cancer patients. GEM and 5-FU have…”
Get full text

Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study by Lippe, P., Tummarello, D., Monterubbianesi, M. C., Silva, R. R., Giuliodori, L., Mari, D., Santo, A., Pasini, F., Cetto, G. L., Rossi, D., Porfiri, E., Cascinu, S., Cellerino, R.

“…Background: The combination of gemcitabine and cisplatin has proven effective in the treatment of advanced non-small-cell lung cancer (NSCLC). However, the…”
Get full text

A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer by Cascinu, S., Silva, R. R., Labianca, R., Barni, S., Mattioli, R., Martignoni, G., Frontini, L., Gasparini, G., Catalano, V., Baldelli, A. M., Giuliodori, L., Agostinelli, R., Catalano, G.

“…Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil…”
Get full text

Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study by Lippe, P, Silva, R R, Giuliodori, L, Cancellieri, M A, Battelli, N, Massacesi, C, Berardi, R, Bisonni, R, Gesuita, R, Cellerino, R

“…The frequency of advanced non-small cell lung cancer (NSCLC) increases with age and more effective and less toxic chemotherapy schedules are needed in elderly…”
Get more information

Granisetron plus dexamethasone in moderately emetogenic chemotherapy : evaluation of activity during three consecutive courses of chemotherapy by SILVA, R. R, BASCIONI, R, GIORGI, F, ACITO, L, GIUSTINI, L, DE SIGNORIBUS, G, MARCELLINI, M, MENICHETTI, E. T, GIULIODORI, L

“…In this study we evaluated the antiemetic activity of a combination of 3 mg granisetron in a short i.v. infusion followed by 12 mg dexamethasone i.v. in 64…”
Get full text

Limiting dilution analysis of IL-2 producing cells: I. Studies of normal human peripheral blood by Moretti, L, Giuliodori, L, Stramigioli, S, Luchetti, F, Baldi, A, Sparaventi, G

“…After marrow transplantation, the interaction of helper T lymphocytes from the donor with the patient alloantigens leads to cellular activation and release of…”
Get more information

Impact of hospice and palliative home care on chemotherapy use at the end of life (EOL) by Bascioni, R., Giorgi, F., Rastelli, F., di Pietro Paolo, M., Brugni, M., Basirat, F., Mulattieri, S., Giuliodori, L., De Signoribus, G., Silva, R. R., Giustini, L.

“…Abstract only…”
Get full text

Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study by Offidani, M, Corvatta, L, Marconi, M, Visani, G, Alesiani, F, Brunori, M, Galieni, P, Catarini, M, Burattini, M, Centurioni, R, Rupoli, S, Scortechini, AR, Giuliodori, L, Candela, M, Capelli, D, Montanari, M, Olivieri, A, Piersantelli, MN, Leoni, P

“…Clinica di Ematologia Polo Ospedaliero-Universitario, Ospedali Riuniti Ancona Universita Politecnica delle Marche. m.offidani@ao-umbertoprimo.marche.it The aim…”
Get full text

Quantitation of T cell depletion by limiting dilution analysis by Moretti, L, Corpuz, S, Giuliodori, L, Stramigioli, S, Martin, P J

“…We evaluated a culture method for enumeration of residual T cells remaining in marrow after treatment with antibody and complement or with immunotoxin. Marrow…”
Get more information

Dexamethasone Alone or in Combination with Ondansetron for the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy

“…The administration of moderately emetogenic drugs such as cyclophosphamide, doxorubicin, epirubicin, and carboplatin often causes nausea and vomiting within 24…”
Get full text

Autologous bone marrow purging with LAK cells by Giuliodori, L, Moretti, L, Stramigioli, S, Luchetti, F, Annibali, G M, Baldi, A

“…In this study we will demonstrate that LAK cells, in vitro, can lyse hematologic neoplastic cells with a minor toxicity of the staminal autologous marrow…”
Get more information

Assessing clinical benefit (CB) of chemotherapy (CT) in advanced non-small cell lung cancer elderly patients by Lippe, P, Silva, R.R, Giuliodori, L, Massacesi, C, Battelli, N, Cellerino, R

Get full text

Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials by Ballatori, Enzo, Roila, Fausto, Ruggeri, Benedetta, De Angelis, Verena, Porzio, Giampiero, Marchetti, Paolo

“…The dose of delivered chemotherapy is important to evaluate the appropriateness of the anticancer treatment. This aspect has been scarcely studied in Italy…”
Get full text

Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients by Lippe, Paolo, Silva, Rosa R, Giuliodori, Luciano, Monterubbianesi, Maria C, Mattioli, Rodolfo, Massacesi, Cristian, Cascinu, Stefano, Tummarello, Diego, Cellerino, Riccardo

“…Cisplatin-based chemotherapy seems to improve the control of non-small cell lung cancer (NSCLC)-related symptoms, but assessment of symptomatic gain in these…”
Get more information

Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients by BASCIONI, R, GIORGI, F, SILVA, R. R, ACITO, L, GIUSTINI, L, DE SIGNORIBUS, G, GIULIODORI, L, TESTA, E

“…In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients…”
Get full text